|
US9012141B2
(en)
|
2000-03-27 |
2015-04-21 |
Advaxis, Inc. |
Compositions and methods comprising KLK3 of FOLH1 antigen
|
|
AU2004224425B2
(en)
*
|
2003-02-06 |
2010-06-24 |
Aduro Biotech |
Modified free-living microbes, vaccine compositions and methods of use thereof
|
|
PT1592441E
(pt)
|
2003-02-06 |
2012-05-21 |
Aduro Biotech |
Listeria atenuada relativamente à entrada em células não patogénicas, vacinas compreendendo a listeria e métodos para sua utilização
|
|
US7695725B2
(en)
*
|
2003-02-06 |
2010-04-13 |
Aduro Biotech |
Modified free-living microbes, vaccine compositions and methods of use thereof
|
|
CA2521594A1
(en)
*
|
2003-04-11 |
2004-10-28 |
Medimmune, Inc. |
Epha2 and non-neoplastic hyperproliferative cell disorders
|
|
US7842289B2
(en)
|
2003-12-24 |
2010-11-30 |
Aduro Biotech |
Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
|
|
WO2006034334A2
(en)
|
2004-09-21 |
2006-03-30 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
|
|
JP2008516614A
(ja)
*
|
2004-10-18 |
2008-05-22 |
メディミューン，インコーポレーテッド |
リステリア増殖のための高細胞密度法
|
|
WO2006047638A2
(en)
*
|
2004-10-27 |
2006-05-04 |
Medimmune, Inc. |
Modulators of epha2 and ephrina1 for the treatment of fibrosis-related disease
|
|
DE102006004612A1
(de)
*
|
2006-02-01 |
2007-08-16 |
Ralf Dr. med. Jochem |
Therapeutische Zusammensetzung zur Vorbeugung und Bekämpfung von Knochenmetastasen
|
|
US20070207171A1
(en)
*
|
2006-03-01 |
2007-09-06 |
Cerus Corporation |
Engineered listeria and methods of use thereof
|
|
US7935804B2
(en)
*
|
2006-03-01 |
2011-05-03 |
Aduro Biotech |
Engineered Listeria and methods of use thereof
|
|
GB2451014B
(en)
|
2006-03-01 |
2010-12-29 |
Anza Therapeutics Inc |
Engineered Listeria comprising a modified ActA-antigen fusion protein and its use as a vaccine
|
|
WO2007103261A2
(en)
*
|
2006-03-01 |
2007-09-13 |
Medimmune, Inc. |
Listeria-based epha2 immunogenic compositions
|
|
US8926993B2
(en)
|
2006-07-17 |
2015-01-06 |
Aduro Biotech |
Methods and compositions using Listeria for enhancing immunogenicity by prime boost
|
|
US8268326B2
(en)
|
2006-08-15 |
2012-09-18 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
|
|
JP2010500879A
(ja)
|
2006-08-15 |
2010-01-14 |
ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア |
Ｈｍｗ−ｍａａ及びその断片を含む組成物、及びその使用方法
|
|
KR101521668B1
(ko)
|
2007-08-30 |
2015-05-28 |
다이이찌 산쿄 가부시키가이샤 |
항ｅｐｈａ２ 항체
|
|
WO2009044272A2
(en)
*
|
2007-10-04 |
2009-04-09 |
000'npt Mbp Gormezis' |
Laser-based vaccine adjuvants
|
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
|
US20140234370A1
(en)
*
|
2009-11-11 |
2014-08-21 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
|
|
WO2009143085A1
(en)
|
2008-05-19 |
2009-11-26 |
Anza Therapeutics, Inc. |
Compositions comprising prfa*mutant listeria and methods of use thereof
|
|
US9017660B2
(en)
*
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
|
US20110129499A1
(en)
|
2008-05-19 |
2011-06-02 |
Paulo Maciag |
Dual delivery system for heterologous antigens
|
|
WO2010071769A2
(en)
*
|
2008-12-12 |
2010-06-24 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Chimeric l. monocytogens in1b protein
|
|
WO2010102140A1
(en)
|
2009-03-04 |
2010-09-10 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising angiogenic factors and methods of use thereof
|
|
EP2498808A4
(en)
*
|
2009-11-11 |
2014-01-08 |
Advaxis |
COMPOSITIONS AND METHOD FOR PREVENTING FLUID MUTATIONS IN THE TREATMENT OF TUMORS WITH HER2 / NEW OVEREXPRESSION
|
|
US10016617B2
(en)
*
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
|
US9128101B2
(en)
|
2010-03-01 |
2015-09-08 |
Caris Life Sciences Switzerland Holdings Gmbh |
Biomarkers for theranostics
|
|
BR112012025593A2
(pt)
|
2010-04-06 |
2019-06-25 |
Caris Life Sciences Luxembourg Holdings |
biomarcadores em circulação para doença
|
|
ES2613630T3
(es)
|
2010-05-23 |
2017-05-25 |
Aduro Biotech, Inc. |
Métodos y composiciones que utilizan Listeria para un tratamiento auxiliar del cáncer
|
|
GB2482536B
(en)
*
|
2010-08-05 |
2013-07-24 |
Hera Pharmaceuticals Inc |
Expression of antibody or a fragment thereof in lactobacillus
|
|
DK2608799T3
(en)
*
|
2010-08-24 |
2019-03-18 |
Univ Pittsburgh Commonwealth Sys Higher Education |
INTERLEUKIN 13-RECEPTOR-ALPHA 2-PEPTIDE-BASED BRAIN CANCER VACCINES
|
|
EP2446895A1
(en)
*
|
2010-10-01 |
2012-05-02 |
Stemgen S.P.A. |
EPH receptor expression in tumor stem cells
|
|
US9226958B2
(en)
|
2010-10-01 |
2016-01-05 |
University Of Georgia Research Foundation, Inc. |
Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
|
|
WO2012125551A1
(en)
|
2011-03-11 |
2012-09-20 |
Advaxis |
Listeria-based adjuvants
|
|
WO2013052710A1
(en)
*
|
2011-10-04 |
2013-04-11 |
Expression Pathology, Inc. |
Srm/mrm assay for the ephrin type-a receptor 2 protein
|
|
SG11201405605VA
(en)
|
2012-03-12 |
2014-10-30 |
Advaxis Inc |
SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT
|
|
SI3536334T1
(sl)
|
2012-05-16 |
2021-11-30 |
Stemline Therapeutics Inc. |
Cepiva proti raku, ki ciljajo na rakave matične celice
|
|
NZ702392A
(en)
|
2012-06-08 |
2017-03-31 |
Aduro Biotech |
Compositions and methods for cancer immunotherapy
|
|
CA2888678A1
(en)
|
2012-11-06 |
2014-05-15 |
Aduro Biotech, Inc. |
Facultatively attenuated bacterial species and methods of preparation and use thereof
|
|
WO2014093936A1
(en)
|
2012-12-13 |
2014-06-19 |
Aduro Biotech, Inc. |
Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
|
|
JP2016503655A
(ja)
|
2012-12-27 |
2016-02-08 |
アデュロ バイオテック，インコーポレイテッド |
リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用
|
|
US20140329889A1
(en)
|
2013-05-03 |
2014-11-06 |
The Regents Of The University Of California |
Cyclic di-nucleotide induction of type i interferon
|
|
CU24377B1
(es)
|
2013-05-18 |
2018-12-05 |
Aduro Biotech Inc |
Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
|
|
US9549944B2
(en)
|
2013-05-18 |
2017-01-24 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
|
|
CA2947677A1
(en)
*
|
2014-05-02 |
2015-11-05 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
|
|
WO2016061115A1
(en)
|
2014-10-13 |
2016-04-21 |
Providence Health & Services-Oregon D/B/A Providence Portland Medical Center |
Bacterial vaccines deficient in the 2-c-methyl-d-erythritol-4-phosphate pathway and methods of preparation and use thereof
|
|
EP3207142A4
(en)
*
|
2014-10-14 |
2018-07-04 |
The Trustees Of The University Of Pennsylvania |
Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
|
|
WO2016073381A1
(en)
|
2014-11-03 |
2016-05-12 |
Cerus Corporation |
Compositions and methods for improved car-t cell therapies
|
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
EA201890149A1
(ru)
|
2015-06-26 |
2018-07-31 |
Сирус Корпорейшн |
Композиции криопреципитатов и способы их получения
|
|
US10799533B2
(en)
|
2015-10-23 |
2020-10-13 |
Cerus Corporation |
Plasma compositions and methods of use thereof
|
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
|
CN110268264B
(zh)
|
2016-12-23 |
2024-07-02 |
塞鲁斯公司 |
使用化合物结合的基材测试和筛选的系统和方法
|
|
EP4606379A3
(en)
|
2017-03-03 |
2025-11-19 |
Cerus Corporation |
Kits and methods for preparing pathogen-inactivated platelet compositions
|
|
JP7311518B2
(ja)
|
2017-12-29 |
2023-07-19 |
シーラス コーポレイション |
生物学的流体を処理するためのシステムおよび方法
|
|
WO2020263745A1
(en)
|
2019-06-22 |
2020-12-30 |
Cerus Corporation |
Systems and methods for implementing treatment of biological fluids
|
|
JP7576052B2
(ja)
|
2019-06-22 |
2024-10-30 |
シーラス コーポレイション |
生物学的流体処理システム
|
|
EP3991179A1
(en)
|
2019-06-28 |
2022-05-04 |
Cerus Corporation |
System and methods for implementing a biological fluid treatment device
|
|
CN114015644A
(zh)
*
|
2021-11-05 |
2022-02-08 |
成都生物制品研究所有限责任公司 |
一种单一病毒收获液的生产方法
|
|
CN114848654B
(zh)
*
|
2022-04-18 |
2024-04-05 |
武汉大学 |
阿司匹林在制备用于引起肿瘤免疫原性细胞死亡的药物中的应用
|